Alligator Bioscience to Host Virtual Key Opinion Leader Event on Mitazalimab Latest Interim Phase 2 Data in 1st Line Metastatic Pancreatic Cancer

June 27, 2023 – 9:00 AM ET / 3:00 PM CET Featuring Dr. Zev Wainberg from UCLA Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will host a virtual Key Opinion Leader (KOL) event on the interim efficacy data from the OPTIMIZE-1 Phase 2 study evaluating mitazalimab as first-line treatment for pancreatic cancer patients. The webinar will take place on Tuesday, June 27, 2023 at 9:00 AM ET / 3:00 PM CET. To register for the event, please click here. The event will feature Dr. Zev Wainberg, Professor of Medicine at University of California, Los Angeles (UCLA) and co-director of the UCLA Gastrointestinal (GI) Oncology Program, who will present the unmet medical need and current treatment landscape for patients suffering from metastatic pancreatic cancer, along with the potential for mitazalimab to provide an effective and safe first-line treatment solution. Additionally, in a discussion moderated by Alligator Chief Medical Officer Dr. Sumeet Ambarkhane, we will provide insights into the latest interim efficacy readout and survival data from the OPTIMIZE-1 Phase 2 study evaluating CD40 agonist mitazalimab in combination with chemotherapy (mFOLFIRINOX) in 1st line metastatic pancreatic cancer. As a reminder, the latest interim data analysis published on January 2nd showed encouraging outcomes for pancreatic cancer patients treated with mitazalimab combined with chemotherapy, achieving 52% Objective Response Rate (ORR) and Disease Control Rate (DCR) of >90%. A live question and answer session will follow the formal presentations. For further information, please contact: Søren Bregenholt, CEO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 LifeSci Advisors Investor Relations Guillaume van Renterghem E-mail: [email protected] Phone: +41 (0) 76 735 01 31 About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com.

The release as fetched from its publisher. alligatorbioscience.se ↗